Notes From The Past Chair

Dr. Mary Lipscomb
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This is a goodbye as Chair of the Department of Pathology, a position I held from
April 1, 1994 to June 30, 2006. I am delighted that Dr. Brian Hjelle has agreed to
serve as Interim Chair as the search for a new permanent Chair continues. On July
1, I began a new job as Executive Dean of the School of Medicine and am finding
this an exciting new challenge. My new responsibilities will be to assist Dean Paul
Roth, who is now also the Executive VP of the Health Sciences Center, in carrying
out the total mission of the SOM. I'm pleased that in that new capacity I am also still a faculty member
in the Department of Pathology. I plan to continue my research, although on a more time-limited basis.
There have been many highlights for me in this past 12 years. An important achievement was building
on an already strong faculty to recruit new faculty to attain one now truly outstanding. Various members
of our faculty have achieved true national acclaim and our divisions and programs are stellar. Specific
achievements of which I am particularly proud were winning a NIH-sponsored Specialized Center of
Research (SCOR) in Asthma award, now in its tenth year. Secondly, I participated in crafting TriCore
Reference Laboratories. Finally, I feel very proud of how our faculty and the discipline of pathology has
become an integral part of all aspects of the medical student curriculum, particularly in Phase 1. As some
of you know, the School of Medicine became completely integrated in Phase 1 of the curriculum (the old
Years l and 2 of the traditional curriculum) in l 993. The various disciplines in the SOM struggled for a
time about how to assure their particular discipline would be integrated into the l 8-months that would
constitute Phase 1. Pathology has been particularly successful in this endeavor. Now several Pathology
faculty are block leaders. Our current Vice Chair for Undergraduate Medical Education, Dr. Alexis Harris, is recognized as one of the School's leaders in education. If you are one of our former faculty or
trainees, I think you can brag on the time that you spent with us. If you are currently still connected by
virtue of participating in one of the Department's missions, thank you for all your help over the years. I
know you will continue to support the Department under Dr. Hjelle's leadership and then under the leadership of our next permanent chair.

Brian Hjelle to serve as Interim Chair
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Phase 1 of the new education building under construction on the
HSC campus is due to be finished in Nove'mber of 2006. Eventually costing $49 million and encompassing 167,500 sq ft, this
structure will house the bookstore, a food court, seminar rooms,
classrooms, lecture halls and a learning center.

HSC administration announced that Professor Brian Hjelle has agreed to serve as interim chairperson of
the Department of Pathology until a permanent chair can be named. Dr. Hjelle will replace Dr. Lipscomb,
who, on July 1, will move from being the Chairperson of Pathology to being the Executive Dean of the
School of Medicine.
Brian is a graduate of the University of California at Berkeley, and received his MD from the
Johns Hopkins School of Medicine. He then completed an internship in Internal Medicine in Virginia followed by a residency in Laboratory Medicine at UCSF and several years of training in molecular virology
and oncology with Nobel Laureate J Michael Bishop. Brian has been having a successful track record of
funding from NIH, having had a role in the acquisition of no less than $20 million of federal grants as
coinvestigator, Project Director on program project grants, and as Pl. He has been involved in numerous
Departmental, HSC and SOM committees, including five years of service as the Vice Chair for Research
in Pathology and extensive involvement with the Institutional Biosafety and Institutional Animal Care and
Use Committees. He is a principal architect of the newly formed Center for Infectious Diseases and Immunity, and played a central role in the establishment of the Infectious Diseases and Inflammation Program
graduate training grant, which supports both graduate students and postdoctoral fellows. He is known for
his work in the field of viral zoonotic diseases, efforts that have brought him international acclaim leading
to consultative and collaborative roles with WHO and other sponsors in countries such as China, Brazil,
Sweden, Paraguay and Chile. We are fortunate that Brian has agreed take on the task of leading the
department until a permanent successor can be found.

A Great Year for FEF Winners!

Dr. Kathy Foucar

Thanks to broad support for our Foucar Endowment Fund (FEF), the Department of Pathology Training Fund, we were able to fund nine educational travel
awards for pathology residents, hematopathology fellows and a post sophomore
fellow here at UNM! These educational travel awards included the US Canadian Academy of Pathology, the American Academy of Forensic Sciences, the
Tutorial on Neoplastic Hematopathology, as well as the ASCP resident review
course. I am also thrilled to announce that we were simultaneously able to fund
nine research projects that involved pathology residents, our post sophomore
student fellow, and a hematopathology fellow. These research projects included such topics as "lmmunohistochemical expression of glucose transporter- l in endocervical neoplasia," as well
as "Genetic markers in subtypes of diffuse large B-cell lymphoma using tissue fluorescence in situ hybridization." The successful development of paraffin FISH testing here at University of New Mexico/TriCore Reference
Laboratories has opened the door for much more expanded translational research projects on our archived
tissue specimens. A recently approved project entitled, "Cytogenetic analysis of granular renal neoplasms by
interphase fluorescence in situ hybridization," will utilize this new testing modality on archived surgical pathology specimens. Obviously, all of our translational research projects have been evaluated and approved by
our Human Research Review Committee (HRRC). Such approval is a requirement before these proposals can be
submitted to the committee that evaluates applications for research support from the FEF.
The level of enthusiasm of all of our trainees for this special type of educational and translational
research support remains very high. I want to thank all of you who have contributed to this endowed fund!

2006 Annual Staff Awards

Some of the 22 Pathology employees who received Staff Awards
during the 9th annual ceremony in June 2006.
A committee of faculty, together with the Chair Mary Lipscomb, utilized two levels of achievement to award
staff - Outstanding and Commendable.

Listed in alphabetical order, the awardees are:
Virginie Bondu-Hawkins, Linda Borgman, Artemis Chakerian, Susan Dellinger, Nicki Garcia, Michael Grady,
Charlene Hensler, Janet Kelly, Hadya Khawajo, Debbie Lovato, LeeAnn Mortinez, George Montoya,
Connie Peceny, Nancy Risenhoover Ellen Rivera, Elsa Romero, Mary Sisley, Christy Tarleton, Jackie Tuck,
Sandy Turner, Jin Wu, and Chunyan Ye.

Former Pathology Chair, Mary Lipscomb,
is congratulated for her new position as
Executive Dean of the SOM by the
outgoing ED, John Trotter.

Cytogenetics

Dr. John Hozier

FISH in the Lab
FISH (fluorescence in situ hybridization) is the technique we use to visualize changes in chromosome organization in both clinical and research laboratory settings. In the clinical lab (directed by Drs. John Hozier and
Kaaren Reichard), we can detect chromosome abnormalities that are helpful in the diagnosis of genetic
diseases, including birth and developmental defects, and cancer. It is possible to see, in the cell nucleus,
any gene of interest, and count the number of copies. Any deviation from the normal gene number of
two per nucleus usually is associated with disease. Rearrangements of chromosomes also are important
in cancer, and FISH provides information on such rearrangements as well. The current research focus is
on FISH analysis of chromosome alterations in pediatric and adult cancers to discover possible indicators
of response to therapy and markers of long-term survival. We want to continue to involve pathology
residents and fellows in as many of these projects as possible.

Fluorescence in situ hybridization on a
paraffin-embedded whole tissue section.
A BCL 1 (orange signal) and IGH (green signal)
probe set is shown which detects the t( 11; l 4)(q l 3;q32)
seen in mantle cell lymphoma. The presence of the
BCL l -IGH fusion is seen as overlapping orange and
green signals (yellow) in the nuclei.

